[{"x_label":"Neuroblastoma  (Dataset = All Cohorts, Specimen = Pediatric Primary and Relapse Tumors, N = 318)","specimen_descriptor_fill":"Pediatric Primary Tumors","box_sample_count":304,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"All Cohorts","Disease":"Neuroblastoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000621","MONDO":"MONDO_0005072","GTEx_tissue_subgroup_UBERON":"","TPM_mean":29.06,"TPM_sd":18.32,"TPM_min":2.63,"TPM_25th_percentile":13.48,"TPM_median":24.7,"TPM_75th_percentile":43.16,"TPM_max":88.29},{"x_label":"Neuroblastoma  (Dataset = All Cohorts, Specimen = Pediatric Primary and Relapse Tumors, N = 318)","specimen_descriptor_fill":"Pediatric Relapse Tumors","box_sample_count":14,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"All Cohorts","Disease":"Neuroblastoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000621","MONDO":"MONDO_0005072","GTEx_tissue_subgroup_UBERON":"","TPM_mean":10.31,"TPM_sd":4.72,"TPM_min":3.34,"TPM_25th_percentile":7.21,"TPM_median":10.36,"TPM_75th_percentile":12.36,"TPM_max":19.43},{"x_label":"Neuroblastoma  (Dataset = TARGET, Specimen = Pediatric Primary and Relapse Tumors, N = 137)","specimen_descriptor_fill":"Pediatric Primary Tumors","box_sample_count":129,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TARGET","Disease":"Neuroblastoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000621","MONDO":"MONDO_0005072","GTEx_tissue_subgroup_UBERON":"","TPM_mean":12.92,"TPM_sd":5.32,"TPM_min":2.63,"TPM_25th_percentile":9.29,"TPM_median":12.46,"TPM_75th_percentile":16.23,"TPM_max":26.87},{"x_label":"Neuroblastoma  (Dataset = TARGET, Specimen = Pediatric Primary and Relapse Tumors, N = 137)","specimen_descriptor_fill":"Pediatric Relapse Tumors","box_sample_count":8,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TARGET","Disease":"Neuroblastoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000621","MONDO":"MONDO_0005072","GTEx_tissue_subgroup_UBERON":"","TPM_mean":12.76,"TPM_sd":4.15,"TPM_min":8.02,"TPM_25th_percentile":10.54,"TPM_median":11.94,"TPM_75th_percentile":14.48,"TPM_max":19.43},{"x_label":"Glioblastoma Multiforme  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 165)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":152,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Glioblastoma Multiforme","GTEx_tissue_subgroup":"","EFO":"EFO_0000519","MONDO":"MONDO_0018177","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.14,"TPM_sd":1.52,"TPM_min":0.85,"TPM_25th_percentile":3.01,"TPM_median":4.01,"TPM_75th_percentile":4.99,"TPM_max":9.03},{"x_label":"Glioblastoma Multiforme  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 165)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":13,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Glioblastoma Multiforme","GTEx_tissue_subgroup":"","EFO":"EFO_0000519","MONDO":"MONDO_0018177","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.94,"TPM_sd":2.97,"TPM_min":0.99,"TPM_25th_percentile":3.9,"TPM_median":4.34,"TPM_75th_percentile":4.9,"TPM_max":12.09},{"x_label":"Low-grade glioma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 521)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":507,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Low-grade glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0021637","MONDO":"MONDO_0021637","GTEx_tissue_subgroup_UBERON":"","TPM_mean":5.6,"TPM_sd":1.98,"TPM_min":1.79,"TPM_25th_percentile":4.16,"TPM_median":5.37,"TPM_75th_percentile":6.73,"TPM_max":13.23},{"x_label":"Low-grade glioma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 521)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":14,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Low-grade glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0021637","MONDO":"MONDO_0021637","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.03,"TPM_sd":1.37,"TPM_min":1.41,"TPM_25th_percentile":3.3,"TPM_median":3.98,"TPM_75th_percentile":4.79,"TPM_max":7.19},{"x_label":"Ovarian Serous Cystadenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 378)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":373,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Ovarian Serous Cystadenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1000043","MONDO":"MONDO_0006046","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.23,"TPM_sd":1.58,"TPM_min":1.1,"TPM_25th_percentile":3.18,"TPM_median":4.02,"TPM_75th_percentile":5,"TPM_max":11.23},{"x_label":"Ovarian Serous Cystadenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 378)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":5,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Ovarian Serous Cystadenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1000043","MONDO":"MONDO_0006046","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.23,"TPM_sd":1.72,"TPM_min":1.63,"TPM_25th_percentile":3.39,"TPM_median":4.89,"TPM_75th_percentile":5.41,"TPM_max":5.84},{"x_label":"Sarcoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 261)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":258,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Sarcoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000691","MONDO":"MONDO_0005089","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.43,"TPM_sd":2.19,"TPM_min":1.08,"TPM_25th_percentile":2.92,"TPM_median":4.11,"TPM_75th_percentile":5.44,"TPM_max":19.22},{"x_label":"Sarcoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 261)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":3,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Sarcoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000691","MONDO":"MONDO_0005089","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.45,"TPM_sd":1.65,"TPM_min":2.79,"TPM_25th_percentile":3.63,"TPM_median":4.48,"TPM_75th_percentile":5.28,"TPM_max":6.08}]